MSK picks brain can­cer ex­pert Lisa DeAn­ge­lis as its next CMO — fol­low­ing José Basel­ga’s con­tro­ver­sial ex­it

6 years ago
R&D

Roche vet Jean-Jacques Ga­raud woos in­ter­na­tion­al be­liev­ers in his French star­tup's take on sep­tic shock

6 years ago
Financing
Startups

Roche's Tecen­triq ex­cels in an­oth­er lung can­cer study

6 years ago
R&D
Pharma

Penn team adapts CAR-T tech, reengi­neer­ing mouse cells to treat car­diac fi­bro­sis

6 years ago
R&D

J&J's head-to-head PhI­II da­ta promise drug launch in­to crowd­ed MS mar­ket

6 years ago
R&D

Can­cer drugs among US goods spared from tar­iffs as Chi­na is­sues first ex­emp­tions in trade war

6 years ago
China

Toca­gen shares col­lapse as in­ves­ti­ga­tors read last rites for PhI­II brain can­cer study

6 years ago
R&D

Look out Alex­ion, Roche breaks out the de­tails on its ri­val rare CNS drug

6 years ago
R&D
Pharma

The mR­NA uni­corn Mod­er­na has more ear­ly-stage hu­man da­ta it wants to show off — reach­ing new peaks in prov­ing the ...

6 years ago
R&D

Atom­wise inks Chi­na deal as list of AI col­lab­o­ra­tions length­ens

6 years ago
Deals
AI

In­vestors lost big as Alzheimer’s R&D went over the cliff in 2019. Will they ever come back?

6 years ago
Bioregnum
Opinion

Big Phar­ma joins £200M UK Biobank se­quenc­ing project; Monopar sets terms for $40M IPO

6 years ago
News Briefing

Promis­ing au­toim­mune biotech bought out as celi­ac drug heads for the clin­ic with a fresh in­fu­sion of cash

6 years ago
R&D

How about a $477M biotech IPO amid Hong Kong protests? Hen­lius will find out

6 years ago
Financing
China

No sur­pris­es in FDA staff re­view for Aim­mune peanut al­ler­gy ther­a­py — fo­cus re­mains on safe­ty, tol­er­a­bil­i­ty pro­file

6 years ago
R&D

Mer­ck KGaA touts FDA 'break­through' sta­tus, block­buster po­ten­tial in bid to woo in­vestors

6 years ago
R&D

Wood­ford fall­out to blame for shrink­ing biotech val­u­a­tions, co-in­vestor says

6 years ago
R&D

Hong Kong strife holds up al­most $100M of BioN­Tech's Se­ries B haul

6 years ago
Financing
China

Af­ter plen­ty of due dili­gence, GSK buys one biotech pup in the ‘$500M’ Aval­on lit­ter for its pipeline

6 years ago
Deals

FDA de­vel­op­ing guid­ance on re­al-world da­ta qual­i­ty is­sues, of­fi­cials say

6 years ago
FDA+

Ital­ian gene ther­a­py play­er draws new in­vestor from Chi­na for its an­swer to CAR-T re­laps­es

6 years ago
Financing
Cell/Gene Tx

Sanofi takes a $260M hit to ex­tri­cate it­self from a dis­as­trous al­liance with Lex­i­con

6 years ago
R&D

The End­points 100: No­var­tis gets 'poor' grade on da­ta scan­dal, Ned Sharp­less is­n't a 'wow' and that Cana­da drug ...

6 years ago
Editor's note

Atom­wise, On­coStatyx launch JV to tar­get triple-neg­a­tive breast can­cer; Can­cer biotech woos for­mer Spark COO John ...

6 years ago
News Briefing
First page Previous page 900901902903904905906 Next page Last page
A service from the Financial Times